Implementation of a Fluorescence-Based Screening Assay Identifies Histamine H3 Receptor Antagonists Clobenpropit and Iodophenpropit as Subunit-Selective N-Methyl-d-Aspartate Receptor Antagonists

N-Methyl-d-aspartate (NMDA) receptors are ligand-gated ion channels that mediate a slow, Ca2+-permeable component of excitatory synaptic transmission in the central nervous system and play a pivotal role in synaptic plasticity, neuronal development, and several neurological diseases. We describe a fluorescence-based assay that measures NMDA receptor-mediated changes in intracellular calcium in a BHK-21 cell line stably expressing NMDA receptor NR2D with NR1 under the control of a tetracycline-inducible promoter (Tet-On). The assay selectively identifies allosteric modulators by using supramaximal concentrations of glutamate and glycine to minimize detection of competitive antagonists. The assay is validated by successfully identifying known noncompetitive, but not competitive NMDA receptor antagonists among 1800 screened compounds from two small focused libraries, including the commercially available library of pharmacologically active compounds. Hits from the primary screen are validated through a secondary screen that used two-electrode voltage-clamp recordings on recombinant NMDA receptors expressed in Xenopus laevis oocytes. This strategy identified several novel modulators of NMDA receptor function, including the histamine H3 receptor antagonists clobenpropit and iodophenpropit, as well as the vanilloid receptor transient receptor potential cation channel, subfamily V, member 1 (TRPV1) antagonist capsazepine. These compounds are noncompetitive antagonists and the histamine H3 receptor ligand showed submicromolar potency at NR1/NR2B NMDA receptors, which raises the possibility that compounds can be developed that act with high potency on both glutamate and histamine receptor systems simultaneously. Furthermore, it is possible that some actions attributed to histamine H3 receptor inhibition in vivo may also involve NMDA receptor antagonism.

[1]  R. Dingledine,et al.  Glutamate Receptor Ion Channels: Structure, Regulation, and Function , 2010, Pharmacological Reviews.

[2]  J. Arrang,et al.  Histamine Potentiates N-Methyl-d-aspartate Receptors by Interacting with an Allosteric Site Distinct from the Polyamine Binding Site , 2010, Journal of Pharmacology and Experimental Therapeutics.

[3]  S. Traynelis,et al.  Control of NMDA Receptor Function by the NR2 Subunit Amino-Terminal Domain , 2009, The Journal of Neuroscience.

[4]  A. A. Romanovsky,et al.  The Transient Receptor Potential Vanilloid-1 Channel in Thermoregulation: A Thermosensor It Is Not , 2009, Pharmacological Reviews.

[5]  R. Dingledine,et al.  Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors. , 2009, Bioorganic & medicinal chemistry.

[6]  A. Mikulecká,et al.  Different effects of two N-methyl-d-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats , 2009, Epilepsy & Behavior.

[7]  M. Leonetti,et al.  Structural Basis of NR2B-Selective Antagonist Recognition by N-Methyl-d-aspartate Receptors , 2009, Molecular Pharmacology.

[8]  M. Krams,et al.  An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder , 2008, Journal of clinical psychopharmacology.

[9]  H. Haas,et al.  Histamine in the nervous system. , 2008, Physiological reviews.

[10]  Shin-Da Lee,et al.  Estrous cycle variation of TRPV1-mediated cross-organ sensitization between uterus and NMDA-dependent pelvic-urethra reflex activity. , 2008, American journal of physiology. Endocrinology and metabolism.

[11]  K. Hansen,et al.  Pharmacological characterization of ligands at recombinant NMDA receptor subtypes by electrophysiological recordings and intracellular calcium measurements. , 2008, Combinatorial chemistry & high throughput screening.

[12]  P. Bonaventure,et al.  Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. , 2007, European journal of pharmacology.

[13]  R. Leurs,et al.  The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons. , 2007, European journal of pharmacology.

[14]  S. Dravid,et al.  Subunit‐specific mechanisms and proton sensitivity of NMDA receptor channel block , 2007, The Journal of physiology.

[15]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[16]  A. Hancock,et al.  Detection of multiple H3 receptor affinity states utilizing [3H]A‐349821, a novel, selective, non‐imidazole histamine H3 receptor inverse agonist radioligand , 2006, British journal of pharmacology.

[17]  Rob Leurs,et al.  Evaluation of Histamine H1-, H2-, and H3-Receptor Ligands at the Human Histamine H4 Receptor: Identification of 4-Methylhistamine as the First Potent and Selective H4 Receptor Agonist , 2005, Journal of Pharmacology and Experimental Therapeutics.

[18]  Julian Tirado-Rives,et al.  Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  E. Waxman,et al.  N-methyl-D-aspartate Receptor Subtypes: Multiple Roles in Excitotoxicity and Neurological Disease , 2005, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[20]  Anthony Nicholls,et al.  Variable selection and model validation of 2D and 3D molecular descriptors> , 2004, J. Comput. Aided Mol. Des..

[21]  C. D. Benham,et al.  Capsazepine Protects against Neuronal Injury Caused by Oxygen Glucose Deprivation by Inhibiting Ih , 2003, The Journal of Neuroscience.

[22]  J. Lisman.  Long-term potentiation: outstanding questions and attempted synthesis. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[23]  Y. Cury,et al.  Peripheral tackykinin and excitatory amino acid receptors mediate hyperalgesia induced by Phoneutria nigriventer venom. , 2003, European journal of pharmacology.

[24]  P. Paoletti,et al.  Mapping the Binding Site of the Neuroprotectant Ifenprodil on NMDA Receptors , 2002, The Journal of Neuroscience.

[25]  K. Williams,et al.  Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. , 2002, Molecular pharmacology.

[26]  Nicholas J. Carruthers,et al.  Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. , 2001, Molecular pharmacology.

[27]  P. Krogsgaard‐Larsen,et al.  Ligands for glutamate receptors: design and therapeutic prospects. , 2000, Journal of medicinal chemistry.

[28]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[29]  W. Löscher,et al.  Anticonvulsant effects of eliprodil alone or combined with the glycineB receptor antagonist L-701,324 or the competitive NMDA antagonist CGP 40116 in the amygdala kindling model in rats , 1999, Neuropharmacology.

[30]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[31]  S. Traynelis,et al.  Control of Voltage-Independent Zinc Inhibition of NMDA Receptors by the NR1 Subunit , 1998, The Journal of Neuroscience.

[32]  S. Vicini,et al.  Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. , 1998, Journal of neurophysiology.

[33]  O. Zuiderveld,et al.  Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5‐HT3 receptor revealed , 1995, British journal of pharmacology.

[34]  K. Williams.  Subunit-specific potentiation of recombinant N-methyl-D-aspartate receptors by histamine. , 1994, Molecular pharmacology.

[35]  F. Stephenson,et al.  Optimal expression of cloned NMDAR1/NMDAR2A heteromeric glutamate receptors: a biochemical characterization. , 1993, The Biochemical journal.

[36]  H. Haas,et al.  Histamine potentiates N-methyl-d-aspartate responses in acutely isolated hippocampal neurons , 1993, Neuron.

[37]  J. Bekkers.  Enhancement by histamine of NMDA-mediated synaptic transmission in the hippocampus. , 1993, Science.

[38]  A. Akaike,et al.  Ifenprodil prevents glutamate cytotoxicity via polyamine modulatory sites of N-methyl-D-aspartate receptors in cultured cortical neurons. , 1993, The Journal of pharmacology and experimental therapeutics.

[39]  B. McEwen,et al.  The role of N‐methyl‐D‐asparate receptors in neurogenesis , 2006, Hippocampus.

[40]  W. Fischer,et al.  Effect of clobenpropit, a centrally acting histamine H3-receptor antagonist, on electroshock- and pentylenetetrazol-induced seizures in mice , 1998, Journal of Neural Transmission.